论文部分内容阅读
本文介绍目前尚处于临床试用阶段新合成的蒽环类抗肿瘤抗生素,同时简述蒽环类药物研究的重要动向,主要在抗造血系统肿瘤。一、蒽环类药物发展慨况继阿霉素(doxorubicin,DX)和柔红霉素(daunorubicin,DNR)后,目前已处于临床试用阶段的新蒽环类抗生素有:4-去甲基氧柔红霉素,表阿霉素,4′-去氧阿霉素,4′碘-4′去氧阿霉素,红比腙,4-去甲基柔红霉素,THP-阿霉素,AD-32,阿克拉霉素A、Detorubicin 和Menogaril。(一)毒性降低新蒽环类药物多为缓慢释放型,或许为患者对这些药物有较好耐受性的部分原因。新蒽环类药物
This article describes the newly synthesized anthracycline antitumor antibiotics that are currently in clinical trials and briefly describes the important trends in anthracycline research, mainly in the hematopoietic tumors. First, the development of anthracycline condition Following the doxorubicin (DX) and daunorubicin (DNR), the new anthracycline antibiotics are currently in clinical trial phase: 4-demethoxy Daunorubicin, epirubicin, 4’-deoxy doxorubicin, 4 ’iodo-4’ deoxy doxorubicin, rubrosporone, 4- desmethyl daunorubicin, THP-doxorubicin , AD-32, Aclacinomycin A, Detorubicin and Menogaril. (A) reduce the toxicity of the new anthracycline mostly slow release, perhaps for patients with these drugs have better tolerance of some of the reasons. New anthracycline drugs